Načítá se...
The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients
BACKGROUND: Prostate cancer (PCa) is characterised by great heterogeneity of the disease progression rate. Tumours range from insignificant and not life threatening to high risk for relapse ones. Consequently, a large number of patients undergo unnecessary treatment. miR-145 is a well-documented tum...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3694240/ https://ncbi.nlm.nih.gov/pubmed/23703249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.250 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|